Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Merck
AstraZeneca
McKinsey
Colorcon

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for GS-4997

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug GS-4997?

GS-4997 is an investigational drug.

There have been 9 clinical trials for GS-4997. The most recent clinical trial was a Phase 2 trial, which was initiated on January 30th 2017.

The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Hepatitis, Alcoholic. The leading clinical trial sponsors are Gilead Sciences, HepQuant, LLC, and [disabled in preview].

There are twelve US patents protecting this investigational drug and one hundred and seventy-one international patents.

Recent Clinical Trials for GS-4997
TitleSponsorPhase
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) FibrosisGilead SciencesPhase 3
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)Gilead SciencesPhase 3
GS-4997 in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)Gilead SciencesPhase 2

See all GS-4997 clinical trials

Clinical Trial Summary for GS-4997

Top disease conditions for GS-4997
Top clinical trial sponsors for GS-4997

See all GS-4997 clinical trials

US Patents for GS-4997

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GS-4997   Start Trial Methods of treating liver disease Gilead Sciences, Inc. (Foster City, CA)   Start Trial
GS-4997   Start Trial Cyclobutyl-imidazolidinone compounds ELI LILLY AND COMPANY (Indianapolis, IN)   Start Trial
GS-4997   Start Trial Apoptosis signal-regulating kinase inhibitors Gilead Sciences, Inc. (Foster City, CA)   Start Trial
GS-4997   Start Trial Apoptosis signal-regulating kinase inhibitor Gilead Sciences, Inc. (Foster City, CA)   Start Trial
GS-4997   Start Trial Apoptosis signal-regulating kinase inhibitor Gilead Sciences, Inc. (Foster City, CA)   Start Trial
GS-4997   Start Trial Apoptosis signal-regulating kinase inhibitor Gilead Sciences, Inc. (Foster City, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GS-4997

Drugname Country Document Number Estimated Expiration Related US Patent
GS-4997 Australia 2015320792 2034-09-24   Start Trial
GS-4997 Australia 2018271289 2034-09-24   Start Trial
GS-4997 Brazil 112017005693 2034-09-24   Start Trial
GS-4997 Canada 2962572 2034-09-24   Start Trial
GS-4997 China 106714841 2034-09-24   Start Trial
GS-4997 Eurasian Patent Organization 201790398 2034-09-24   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Colorcon
Merck
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.